The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality. Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.
But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.
HughesMedicine - Pharmacotherapy Pearls from the Internal Medicine Clinical Pharmacist
Recommended for you
-
The American Geriatrics Society recently published their Alternative Treatments to Selected Medications in reference to the most recent upd...
-
Let’s start with a patient case. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some inflammatory process and...
-
A 55 year old business executive is being discharged from the hospital after a brief admission for cellulitis. His only PMH is HTN and o...
-
Ticagrelor is an antiplatelet medication that is commonly used for a number of cardiovascular conditions. Its mechanism is similar to th...
-
Since it's the time of year again when Lyme disease is a concern for patients in many parts of the United States, I thought it would b...
-
Testing urine for the presence of drugs has a variety of uses including assessing poisoning or overdose, pre-employment testing, substanc...
-
A 65 year old male is being treated for an infection on his forearm that developed purulent drainage within the last few days. He denies ...
-
A 74 year old female patient presents to clinic describing dysuria and urinary frequency that started within the last few days. She has ...
-
Heart failure (HF) is a complex condition characterized by signs of volume overload or symptoms such as dyspnea, exercise intolerance, and f...
-
A previous discussion was about selecting a phosphate repletion product . Selecting a drug product can be confusing because of the similar ...
